Subject(s)
Adult , Female , Humans , Male , Middle Aged , AIDS-Related Opportunistic Infections/immunology , Pneumocystis carinii , Pneumonia, Pneumocystis/immunology , AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/mortality , Cohort Studies , Immunocompromised Host , Pneumonia, Pneumocystis/diagnosis , Pneumonia, Pneumocystis/mortality , Retrospective Studies , Severity of Illness IndexABSTRACT
La terapia antiretroviral (TARV) de alta actividad cambió la epidemiología de la neumonía por Pneumocystis jiroveci (NPj) en pacientes con SIDA. La incidencia global ha descendido y ahora prevalece en pacientes sin TARV o con fracaso de ésta. Además, la restauración inmune por TARV genera una forma de NPj incluida en los síndromes inflamatorios por restauración inmune (SIRI). A fines del 2004, 75,5% de pacientes con infección por VIH en control en el Hospital de Enfermedades Infecciosas Dr. Lucio Córdova tenían TARV. Esta serie describe las características clínicas de la NPj, comparando el grupo con TARV (n: 6) y sin TARV (n: 12). De aquellos con TARV, 83,3% (5/6) estaban con fracaso inmunológico y 16,7% (1/6) en éxito virológico. El recuento de CD4 fue bajo en ambos grupos (mediana 20 céls/mm3 sin TARV y 51 céls/mm3 con TARV). No hubo diferencia en la mayoría de las características de la NPj, tampoco casos de SIRI. El grupo con TARV tuvo menos severidad y complicaciones, y menos indicación de corticoterapia (p 0,023).
Subject(s)
Humans , Male , Adult , Female , HIV Infections/microbiology , HIV Infections/drug therapy , Pneumonia, Pneumocystis/diagnosis , Pneumonia, Pneumocystis/drug therapy , AIDS-Related Opportunistic Infections , Anti-HIV Agents , Antiretroviral Therapy, Highly Active , HIV Infections/complications , HIV Infections/diagnosis , Pneumonia, Pneumocystis/immunologyABSTRACT
OBJETIVO: Trabalhos experimentais demonstram que as defesas do hospedeiro frente ao Pneumocystis carinii incluem interações complexas entre as células imunes, principalmente linfócitos TCD4+ e macrófagos alveolares. Sendo esse um agente importante associado às imunodeficiências, nosso objetivo foi caracterizar a resposta inflamatória em pulmão de necrópsias de pacientes com AIDS. MÉTODOS: Foram selecionadas 25 necrópsias com diagnóstico de pneumonia por Pneumocystis carinii para pesquisa imuno-histoquímica de linfócitos TCD4+, TCD8+, macrófagos CD68+, células NK CD57+ e células com expressão de TNF-alfa. As células imunomarcadas foram quantificadas e analisadas estatisticamente. RESULTADOS: Todos os espécimes evidenciaram elevado parasitismo na luz dos alvéolos. Observou-se espessamento septal com infiltrado inflamatório constituído predominantemente por linfócitos e macrófagos. Houve diminuição no número de linfócitos TCD4+ e aumento de linfócitos TCD8+, macrófagos e células NK. No septo alveolar freqüentemente observaram-se células expressando TNF-alfa. CONCLUSÕES: A imunossupressão relacionada à AIDS induz a diminuição de linfócitos TCD4+ e favorece a permanência de elevado parasitismo. Os componentes celulares que caracterizam o infiltrado inflamatório contribuem para os danos irreversíveis no pulmão desses pacientes.
Subject(s)
Humans , Immunity, Cellular , Immunohistochemistry , Cell Wall/immunology , Pneumocystis/immunology , Pneumonia, Pneumocystis/immunology , Lung/pathology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/immunologyABSTRACT
Antiidiotypic antibodies (antiIds) representing the internal image of some antigenic deteminants have been proposed as surrogate vaccines or, conjugated with toxins, in the immunotherapy of cancer. Experimental studies on antiidiotypic vaccination against fungal infections have been lacking. A conceptually new model of idiotypic vaccination against fungal infection has been recently developed. The vaccine used is monoclonal antibody that in vitro neutralizes the activity of killer toxin from the yeast, Pichia anomala (KT). This is effective against a wide range of fungal pathogens including Candida albicans and Pneumocystis carinii, and is also active against Mycobacterium tuberculosis. In an experimental mouse model, this vaccination was found to confer significant protection against systemic and mucosal infection with C. albicans. Human recombinant killer toxin antibodies and its synthetic derivatives hold promise of a potentially powerful tool against fungal and mycobacterial infections.
Subject(s)
Animals , Antibodies, Anti-Idiotypic/immunology , Candida albicans/immunology , Candidiasis/immunology , Disease Models, Animal , Fungal Vaccines , Humans , Mice , Mycobacterium tuberculosis/immunology , Pneumocystis carinii/immunology , Pneumonia, Pneumocystis/immunology , Tuberculosis, Pulmonary/immunology , VaccinationABSTRACT
OBJECTIVE: To compare mortality of wasting syndrome (WS) versus Pneumocystis carinii pneumonia (PCP) in AIDS patients reported in Puerto Rico after controlling for gender, age, and CD4 levels. METHODS: AIDS patients for which a diagnosis of WS (n = 1,180) or PCP (n = 765), who were reported to the AIDS Surveillance System of Puerto Rico between 1989 and 1992, were used to analyze the mortality risk among these diagnoses using a Cox's proportional hazard regression model. RESULTS: Cox model showed that WS patients had a 14 per cent to 33 per cent reduction in mortality risk compared with PCP patients after adjusting for gender and age (95 per cent confidence level). Mortality risks for males were 18 per cent (95 per cent CI: 1 per cent, 39 per cent) higher than females risk after adjusting for AIDS defining condition and age. It was shown that a decrease in 100 CD4 cells increased the mortality by 37 per cent (95 per cent CI: 16 per cent, 62 per cent) after adjusting for AIDS defining conditions, gender, and age.